Form 4: ProMIS Neurosciences Officer Granted Stock Options

ProMIS Neurosciences Inc. granted 60,000 stock options to Principal Accounting Officer Max A. Milbury with an exercise price of $0.45, vesting over time.

Summary

• Max A. Milbury, the Principal Accounting Officer of ProMIS Neurosciences Inc. (PMN), was granted 60,000 derivative securities in the form of stock options.
• The transaction date for this grant was September 22, 2025.
• Each option has an exercise price of $0.45.
• The options are exercisable for 60,000 common shares of ProMIS Neurosciences Inc.
• The options have an expiration date of September 22, 2035.
• The vesting schedule for these options is 25% on September 1, 2026, with the remaining balance vesting ratably over 36 months thereafter.

Sentiment

Score: 6

Explanation: The grant of stock options to a key officer is generally viewed as a positive for aligning management incentives with shareholder interests, though it's a routine compensation event rather than a significant operational or financial announcement.

Positives

• The grant of stock options aligns the interests of the Principal Accounting Officer, Max A. Milbury, with those of the shareholders, incentivizing long-term performance and value creation.

Future Outlook

The vesting schedule for the options, with initial vesting in September 2026 and subsequent monthly vesting over 36 months, indicates a long-term commitment and incentive structure for the Principal Accounting Officer.

Industry Context

The grant of stock options is a common practice in the biotechnology and pharmaceutical industry to attract, retain, and incentivize key executives, aligning their financial success with the company's long-term performance and shareholder value creation.

Stakeholder Impact

• Shareholders: The option grant aims to align management's long-term interests with shareholder value creation, potentially leading to improved company performance.
• Employees (specifically Max A. Milbury): Provides a significant long-term incentive and compensation component tied to the company's stock performance.

Next Steps

• The options will begin to vest with 25% on September 1, 2026.
• The remaining balance of the options will vest ratably over the subsequent 36 months.

Key Dates

Keywords

ProMIS Neurosciences, PMN, Stock Options, Insider Transaction, Form 4, Executive Compensation, Derivative Securities, Max A. Milbury